SCHEMBL24276770

SCHEMBL24276770

Cc1cc(-c2cc3n(n2)CCN(C(=O)OC(C)(C)C)C3C)cc(C)c1F

nearest known ligand 0.36

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ GRM5 P41594 4/20 0.36
▸ NR1H2 P55055 2/20 0.35
▸ NR1H3 Q13133 2/20 0.35
▸ KAT7 O95251 2/20 0.33
▸ NPSR1 Q6W5P4 2/20 0.33
▸ KAT6A Q92794 1/20 0.33
▸ LMNA P02545 1/20 0.33
▸ USP30 Q70CQ3 3/20 0.33
▸ UCHL1 P09936 1/20 0.33
▸ KAT8 Q9H7Z6 1/20 0.33
▸ ACACB O00763 1/20 0.32
▸ MAPT P10636 1/20 0.32
▸ CNR1 P21554 1/20 0.32
▸ GPR35 Q9HC97 1/20 0.32
▸ GPR55 Q9Y2T6 1/20 0.32
▸ TP53 P04637 1/20 0.32
▸ ALDH1A1 P00352 1/20 0.32
▸ DPP4 P27487 1/20 0.31
▸ SETD7 Q8WTS6 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31692464 0.94 LMNA (0.36) GRM5NR1H2NR1H3KAT7NPSR1
SCHEMBL30622756 0.86 GRM5 (0.45) GRM5NR1H2NR1H3ALDH1A1
SCHEMBL30622819 0.82 NR1H2 (0.37) GRM5NR1H2NR1H3USP30UCHL1
SCHEMBL30623037 0.82 NR1H2 (0.43) GRM5NR1H2NR1H3MAPT
SCHEMBL24276764 0.81 MAP4K4 (0.33) NR1H2NR1H3KAT7NPSR1KAT6A
SCHEMBL24276775 0.81 USP30 (0.33) NR1H2NR1H3KAT7NPSR1KAT6A
SCHEMBL26026951 0.77 GRM5 (0.36) GRM5NR1H2NR1H3NPSR1LMNA
SCHEMBL22279667 0.77 MAP4K4 (0.39) GRM5NR1H2NR1H3NPSR1LMNA
SCHEMBL31692233 0.77 NPSR1 (0.35) NR1H2NR1H3KAT7NPSR1KAT6A
SCHEMBL31692539 0.76 KAT7 (0.35) NR1H2NR1H3KAT7NPSR1KAT6A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12595264-B2 Heterocyclic GLP-1 agonists GASHERBRUM BIO, INC. (US) 2026-04-07 — — US disclosed
US-20230331732-A1 HETEROCYCLIC GLP-1 AGONISTS GASHERBRUM BIO, INC. 2023-10-19 — — US disclosed
US-20230331732-A1 HETEROCYCLIC GLP-1 AGONISTS GASHERBRUM BIO, INC. 2023-10-19 — — US disclosed
US-20230331732-A1 HETEROCYCLIC GLP-1 AGONISTS GASHERBRUM BIO, INC. 2023-10-19 — — US disclosed
EP-4211139-A1 HETEROCYCLIC GLP-1 AGONISTS Gasherbrum Bio, Inc. (US) 2023-07-19 — — EP disclosed
WO-2022052958-A1 HETEROCYCLIC GLP-1 AGONISTS GASHERBRUM BIO, INC. (US) 2022-03-17 — — WO disclosed
WO-2022052958-A1 HETEROCYCLIC GLP-1 AGONISTS GASHERBRUM BIO, INC. (US) 2022-03-17 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12595264-B2 Heterocyclic GLP-1 agonists GLP1R, GIPR, GCGR GRM5 1354/4885NR1H2 532/4885NR1H3 759/4885
US-20230331732-A1 HETEROCYCLIC GLP-1 AGONISTS GLP1R, GIPR, GCGR GRM5 2388/4885NR1H2 1786/4885NR1H3 2594/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback